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Abstract
Background: Research waste is estimated to be very common, but assessments of its prevalence and scope are
rare. As an example, we assessed research waste in clinical research on calcium intake (assessing study design and
endpoint type) and vitamin D supplementation (assessing endpoint type).
Methods: We examined 404 randomised controlled trials (RCTs) and observational studies of calcium intake (diet or
supplements) and bone mineral density (BMD) or fracture, and 547 RCTs of vitamin D supplements, and assessed
the proportion of studies that used surrogate or clinical endpoints. For studies with BMD or fracture as an endpoint,
we estimated when the ‘tipping’ point occurred indicating the need for RCTs with fracture as an endpoint (based
on cumulative meta-analyses of BMD RCTs, and chronological review of observational studies), and whether each
study published at least 5y after the tipping point was novel, added new clinical knowledge or was research waste.
Results: Observational studies of calcium intake and BMD or fracture outnumbered RCTs by 3.3–4.5 times. For both
calcium intake and vitamin D supplements, studies using surrogate endpoints outnumbered studies using clinical
endpoints by 1.6–3 times. Of 41 RCT publications of calcium intake and BMD or fracture published at least 5y after
the tipping point in 1994, we considered that 19 (46%) lacked novelty, another 13 (32%) added no new clinical
knowledge, and 30 (73%) were research waste. Of 204 observational study publications of calcium intake and BMD
or fracture, 197 (96%) lacked novelty, another 5 (2%) added no new clinical knowledge, and 202 (99%) were research
waste. Of 39 RCTs of vitamin D supplementation and BMD or fracture published at least 5y after the tipping point in
1999, 14 (36%) lacked novelty, another 13 (33%) added no new clinical knowledge, and 27 (69%) were research waste.
Conclusions: A high proportion of studies of calcium intake since 2000 (95%) and trials of vitamin D supplements
since 2005 (69%) on BMD or fracture represent research waste.
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Background
Redundant research represents a large cost to society and
misuses participants’ resources and altruism. Chalmers and
Glasziou estimated that more than 85% of research might
be wasteful because the wrong research questions are stud-
ied or because of poorly designed studies, inaccessible re-
sults, and biased reporting [1]. Very few studies have
systematically examined research topics for evidence of
waste, or established the methodology for doing so. In these
companion reports [2], we assessed research waste in a sin-
gle field - calcium and vitamin D research.
Calcium intake (through diet or supplements) and
vitamin D supplementation have been very extensively
researched as interventions for older adults for over
30 years. While undertaking recent systematic reviews
[3–8], we noticed that many studies in these fields
seemed to be designed to replicate existing knowledge
rather than to determine new clinically relevant findings.
The large body of published research in these fields al-
lows an assessment of one important aspect of research
waste, the quantity of research conducted that was un-
necessary because existing knowledge was extensive. In
this first report, we use existing databases compiled from
our recent meta-analyses, which collated all studies of
increased calcium intake and all randomised controlled
trials (RCTs) of vitamin D supplements. We assess
whether each study with an endpoint of bone mineral
density (BMD) or fracture constitutes research waste, i.e.
an unnecessary duplication without addressing short-
comings in previous research [9]. We focus on study de-
sign (observational versus RCT) in calcium intake
studies and type of endpoint (surrogate versus clinical)
in vitamin D supplementation RCTs.
Methods
Literature search and study selection
Calcium intake studies
The literature search has previously been published and is
described in full in the Additional file 1: Supplementary
Methods, Table S1, Figure S1 [7, 8]. Briefly, we identified
404 RCTs and observational studies (cohort, case-control,
or cross-sectional studies) published before September
2014 of calcium, milk, or dairy intake, or calcium supple-
ments with fracture or BMD as outcomes in participants
> 50 years who had no major systemic illnesses other than
osteoporosis. As a secondary analysis, we also assessed
studies with cardiovascular and cancer endpoints.
Vitamin D supplementation RCTs
The search is described in full in the Additional file 1:
Supplementary Methods, Tables S2-S3, Figure S2. Briefly,
we identified 547 RCTs of vitamin D supplements in
adults (>18y) published before December 2015 and clas-
sified them by the clinical relevance of their endpoints.
We categorised each RCT according to whether clinical
or surrogate endpoints were reported in the Abstract,
using the Institute of Medicine’s definition of surrogate
outcomes as “biomarker[s] intended to substitute for a
clinical endpoint [and] expected to predict clinical bene-
fit (or harm …) based on epidemiologic, therapeutic,
pathophysiologic, or other scientific evidence” [10]. If
there were multiple publications or endpoints, we in-
cluded the study report with the most relevant clinical
endpoint, or if there were no clinical endpoints, the
study report with the most clinically relevant surrogate
endpoint (Table 1).
Table 1 Classification of endpoints in 547 randomised
controlled trials of vitamin D supplementation
Endpointa Number of RCTs
Clinical endpoints
Fracture 18
Falls 17
Respiratory (eg asthma, COPD, URTI) 14
Musculoskeletal symptoms/Pain 11
Pregnancy outcomes 9
Tuberculosis 8
Multiple Sclerosis 7
Mood 6
SLE/Rheumatoid Arthritis 6
Other 41
Surrogate endpoints
Bone mineral density 57
25OHD only 49
HbA1c or measures of glycaemia 42
Blood pressure 38
Basic biochemistry 37
Bone turnover markers 31
25OHD, vitamin D metabolites and/or PTH only 24
Muscle Strength 16
Body weight 15
Physical performance tests 14
Vascular properties 7
Hepatitis C viral load 5
Lung function tests 4
Lipids 4
Other laboratory tests/assays 51
Other endpoints 16
Abbreviations: COPD chronic obstructive pulmonary disease, URTI upper
respiratory tract infection, SLE Systemic lupus erythematosus, 25OHD 25
hydroxyvitamin D, PTH parathyroid hormone
amany trials reported more than 1 endpoint in the abstract. The most clinically
relevant endpoint was used for each study
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Determination of research waste
For observational studies of calcium intake, we exam-
ined the results of publications chronologically and by
consensus (MB, AG) determined the ‘tipping’ point - the
time at which the hypothesis that calcium intake was as-
sociated with BMD or fracture had been generated and
warranted testing in RCTs. For RCTs of calcium intake
or vitamin D supplements, we conducted cumulative
meta-analyses for BMD, a surrogate endpoint for the
clinical endpoint of fracture. These meta-analyses were
based on previous systematic reviews of calcium intake
(with or without vitamin D supplements) and BMD [8]
and vitamin D supplements (used as monotherapy, such
that treatment groups only differed by vitamin D use) on
BMD [6]. We then determined by consensus (MB, AG)
if a ‘tipping’ point occurred: that is, the time at which
the treatment effect was established and RCTs were re-
quired to investigate efficacy for the clinically meaning-
ful outcome of fracture. For each category of research,
we allowed a 5 year period after the tipping point, for
publication of research in progress and dissemination
and uptake of existing knowledge.
Each subsequent publication was independently
reviewed by two authors (MB, AG). Firstly, we deter-
mined whether its study design was novel, and sec-
ondly whether it added to existing clinical knowledge
and then, taking into account both these factors in a
stepwise fashion, whether it represented research
waste. These assessments were not based on study re-
sults. We considered a study novel when the popula-
tion group, intervention, or dose did not overlap with
existing publications, or there were potentially import-
ant novel features in the study design. Studies not
considered novel were classified as research waste. We
considered a study added to existing clinical know-
ledge if, by its design, it could produce results that
might potentially modify the existing conclusion that
RCTs with fracture as an endpoint were required.
Studies that did not add to existing knowledge were
considered research waste. Thus, a study could be
classified as novel (e.g. a previously unstudied popula-
tion) but if it could not add to existing knowledge, it
was classified as research waste. Assessments were
performed independently and any disagreements re-
solved by discussion. Agreement between assessors for
novelty was 69–92%, for addition of knowledge 80–
98%, and for waste 76–98%.
Statistics
Cumulative meta-analyses were performed using ran-
dom effects meta-analyses based on previously published
data [6, 8] using Comprehensive Meta-Analysis (Version
2, Biostat, Englewood New Jersey, USA). P-values < 0.05
were considered statistically significant.
Results
Calcium intake studies
Study design
Figure 1 shows the number of publications of calcium in-
take with BMD or fracture as an endpoint over time, by
endpoint and study design. Observational studies outnum-
ber RCTs by 3.3–4.5 times, and studies with BMD as an
endpoint outnumber studies with fracture as an endpoint
by 1.6–2.2 times. By 2014, the number of RCTs with either
endpoint had plateaued, while the number of observa-
tional studies continued to steadily increase. For example,
between 2009 and 13, there were 43 publications from ob-
servational studies and 8 from RCTs with BMD as an end-
point, and 31 publications from observational studies and
3 from RCTs with fracture as an endpoint.
Table 2 shows the secondary analysis results with the
number of publications of calcium intake with clinical
non-skeletal endpoints by study design. Observational
studies outnumber RCTs by 3.4–43 times. Despite the
very large number of observational studies, only two
RCTs had a primary non-skeletal endpoint.
Determination of tipping point
We performed cumulative meta-analyses of the effect of
increasing calcium intake on lumbar spine (Fig. 2) or
femoral neck BMD (Fig. 3) in RCTs at 1y and 2y. By the
end of 1994, the meta-analyses show statistically signifi-
cant increases in BMD at the lumbar spine of 1.4% (95%
CI 0.3, 2.6) at 1y from 7 RCTs involving 792 partici-
pants, and 1.4% (95% CI 0.7, 2.2) at 2y from 8 RCTs in-
volving 852 participants. Likewise, by this time the
pooled effect was 1.4–1.8% at the femoral neck at 1-2y
from 5 RCTs involving 450–471 participants. The pooled
effect sizes change little with the addition of data from
later RCTs. By the end of 1994, RCTs had been con-
ducted in most clinically relevant populations, including
early and late post-menopausal women, men, people
with recent fractures, different ethnic populations, and
cohorts with low calcium intake. In addition, different
doses of calcium supplements, different supplements,
and milk products had all been evaluated in RCTs (Add-
itional file 1: Table S4).
The first cohort study with more than 100 fractures and
10,000 participants was published in 1991, and by the end
of 1994 there were 6 publications from cohort studies in-
volving > 28,000 participants with > 600 hip fractures. By
this time, 24 observational studies (6 cohort, 18 case-con-
trol, and 2 cross-sectional studies) had reported on the re-
lationship between dietary calcium, dairy or milk intake or
calcium supplements and fracture in cohorts with a wide
variety of clinical characteristics.
We therefore defined 1994 as the tipping point for cal-
cium intake and fractures. By this time, observational
studies had reported that calcium intake might be
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associated with fracture risk, and RCTs had confirmed
that increasing calcium intake increased the surrogate
endpoint of BMD. Thus, further RCTs with BMD as an
endpoint or observational studies with either BMD or
fracture endpoints were unnecessary unless there was a
novel hypothesis to be tested. Allowing 5y for dissemin-
ation of this information, we considered whether publi-
cations from 2000 onwards represented research waste.
Estimating research waste
Of 41 RCTs publications from 2000 onwards (Additional
file 1: Table S4), 19 reported fracture data. Seven RCTs
had a primary endpoint of fracture and were considered
novel and not waste. One publication was a novel ex-
ploratory analysis of a previous RCT which had fracture
as the primary endpoint, but did not add new clinical
knowledge and we considered it research waste. Three
RCTs with other novel primary endpoints reported frac-
ture data as a secondary endpoint, but none added new
clinical knowledge because of their small size and few
fracture events. We considered 1 of the 3 publications to
be research waste because it did not report the primary
Table 2 Publications of calcium intake with non-skeletal
endpoints by study design
Endpoint Observational studies RCTa
Cross-sectional Case-control Cohort Total
IHD/MI 1 4 27 31 9b
Stroke 1 2 25 27 8b
Cancer (any site) 0 188 112 300 7c
Colorectal cancer 0 49 45 94 3c
Breast cancer 0 25 25 50 3c
Prostate cancer 0 34 32 66 2c
Colorectal adenoma 3 14 8 25 2
Abbreviation: IHD/MI ischaemic heart disease or myocardial infarction, RCT
randomised controlled trial
aTwo RCTs had colorectal adenoma as the primary endpoint. All other RCTs
reported data as secondary endpoints
bUnpublished data for myocardial infarction and stroke from an additional 11
RCTs published in meta-analyses [25, 26]
cUnpublished data for cancer published in a meta-analysis [27] from an
additional 6 RCTs for total cancer and colorectal cancer, 4 RCTs for breast
cancer, and 2 RCTs for prostate cancer
Fig. 1 Number of publications over time of calcium intake with bone mineral density (left panels) or fracture (right panels) as endpoints by study
design over time
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endpoint of the study, instead being a secondary publica-
tion that only reported fracture data. The major
bone-related focus of the remaining 30 RCTs was BMD,
either as the primary (n = 23) or secondary (n = 7) end-
point. Eight of these 30 RCTs reported fracture data as a
secondary endpoint. Of these 30 RCTs, we considered
11 novel (8 novel study design, 2 novel population
groups, 1 novel dose/population), but only 2 of these 11
RCTs added new clinical knowledge, and we considered
that 28 of the 30 RCTs were research waste. Thus, of the
41 RCT publications at least 5y after the tipping point,
19 (46%) lacked novelty, another 13 (32%) did not add
new clinical knowledge, and overall we considered 30
(73%) of these RCT publications were research waste.
Twenty-four of the 30 reports were primary publications
of RCTs (n = 4537 participants).
Fig. 2 Cumulative meta-analyses of the effect of increased calcium intake (through supplements or dietary sources) with or without vitamin D supplements
on lumbar spine bone mineral density (BMD) in randomised controlled trials at 1 year (left panel) and 2 years (right panel)
Fig. 3 Cumulative meta-analyses of the effect of increased calcium intake (through supplements or dietary sources) with or without vitamin D
supplements on femoral neck bone mineral density (BMD) in randomised controlled trials at 1 year (left panel) and 2 years (right panel)
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Of 204 observational study publications from 2000 on-
wards, 133 reported data on calcium intake and BMD,
and 82 on fracture (Additional file 1: Table S5). In 51,
26, and 10 publications respectively, a primary purpose
was to examine the relationship between calcium intake
and BMD, or fracture, or both BMD and fracture. In the
other 82, 56, and 1 publications respectively, examining
calcium intake was a secondary hypothesis, with the pri-
mary purpose to either investigate the determinants of
BMD, or fracture risk, or both BMD and fracture risk,
or to examine the relationship between a specific factor
and these endpoints. We considered that 4/133 publica-
tions reporting BMD relationships and 3/82 reporting
fracture relationships were novel. In 1 publication con-
sidered a novel study design, the relationship between
calcium intake and BMD was the primary focus. In the
other 6 publications, the relationship between calcium
intake and BMD or fracture was only a secondary focus:
2 examined determinants of fracture and 2 determinants
of BMD in previously unreported clinical situations, and
2 developed predictive models for BMD or fracture. We
considered that 2 of these 7 papers added new clinical
knowledge, whereas the other 5 were research waste.
Thus, of the 204 observational study publications from
2000 onwards, 197 (96%) lacked novelty, another 5 (2%)
did not add new clinical knowledge, and overall we con-
sidered 202 (99%) were research waste. Of the 67 publi-
cations with a primary focus on calcium intake and
BMD or fracture, only 1 was novel, and all were consid-
ered research waste.
Vitamin D supplementation randomised controlled trials
Study classification by endpoint
Figure 4 shows the number of RCTs with clinical endpoints
in the abstract (n = 137) compared with RCTs with surro-
gate but no clinical endpoints in the abstract (n = 410). The
RCTs with surrogate endpoints are further subdivided into
those that only report concentrations of 25-hydroxyvitamin
D, other vitamin D metabolites, and/or parathyroid hor-
mone in the abstract (n = 73) and those that report other
endpoints (n = 337). There has been a steady increase in
the number of RCTs published over time, particularly since
Fig. 4 Numbers of publications of randomised clinical trials of vitamin D supplements over time classified according to the clinical or most
clinically relevant surrogate endpoint reported in the Abstract. Left panel: trials with bone mineral density or fracture. Right panel: all trials
classified according to clinical or surrogate endpoints. 25OHD- 25-hydroxyvitamin D
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2005. Since 2012, there have been more than 50 RCTs pub-
lished each year. RCTs with surrogate endpoints outnum-
ber RCTs with clinical endpoints by 3 times. In RCTs with
skeletal endpoints, RCTs of the surrogate endpoint, BMD
(n = 57), outnumber RCTs with the clinical endpoint of
fracture (n = 18) by 3.2 times.
Determination of tipping point
Figure 5 shows cumulative meta-analyses of the effect of
vitamin D supplements at 1-2y on lumbar spine and
femoral neck BMD in RCTs. By the end of 1999, the
meta-analyses show stable effect sizes for BMD at each
site from 4 RCTs involving > 900 participants. By this
time, vitamin D supplements had no effect on lumbar
spine BMD (n = 918, RR 0.3%, 95% CI -0.1, 0.8), but in-
creased femoral neck BMD by 1.0% (95% CI 0.1, 2.0, n =
975). The pooled effect sizes change little with the
addition of data from later RCTs. We therefore defined
1999 as the tipping point and, allowing 5y for dissemin-
ation of this information, we considered whether publi-
cations from 2005 onwards represented research waste.
Estimating research waste
Thirty-nine RCTs of vitamin D supplements with the
most clinically relevant endpoint of BMD or fracture
were published from 2005 onwards (Additional file 1:
Table S6). In 9, the primary endpoint was fracture and
all were considered novel and not waste. Of the
remaining 30 RCTs that reported BMD data, we consid-
ered that 16 were novel because they included novel de-
signs (n = 6), or populations (n = 10), but only 3 of these
16 studies added new clinical knowledge, and we consid-
ered that 27 of the 30 RCTs were research waste. Thus,
of the 39 RCTs published at least 5y after the tipping
point was reached, 14 (36%) were not novel, another 13
(33%) did not add new clinical knowledge, and overall
we considered 27 (69%) of these RCTs (n = 3264 partici-
pants) were research waste.
Discussion
These results, obtained in a specific field of research,
support the view of Chalmers and Glasziou that a very
high proportion of published research is wasteful. For
both calcium intake and vitamin D supplementation,
both observational studies and RCTs with surrogate end-
points were far more prevalent than RCTs with clinical
endpoints. Thus, observational studies of calcium intake
outnumbered RCTs by at least 3 times, and for both cal-
cium intake and vitamin D supplementation, studies
using surrogate endpoints outnumbered studies using
clinical endpoints by 1.6–3 times. For the skeletal end-
points of BMD and fracture, these imbalances persisted
long after the tipping point when the hypothesis that
calcium intake or vitamin D supplementation might
alter fracture risk had been addressed and answered. Of
RCTs of calcium intake or vitamin D supplementation
and fracture or BMD published at least 5y after the tip-
ping point, 36–46% were not novel, testing hypotheses
about effects on BMD that had previously been estab-
lished. Of those considered novel, 60–80% added no
new clinical knowledge, and amounted to a third of the
published RCTs. Almost all observational studies of cal-
cium intake and BMD or fracture published 5y after the
tipping point were not novel. Thus, we considered that
since 2000, 73% of RCTs, 98% of observational studies,
and 95% of clinical research on calcium intake and BMD
or fracture was wasteful and that since 2005, 69% of
RCTs of vitamin D supplements and BMD or fracture
Fig. 5 Cumulative meta-analyses of the effect of vitamin D supplements (used as monotherapy, such that treatment groups only differed by vitamin
D use) on lumbar spine (left panel) and femoral neck bone mineral density (BMD) (right panel) in randomised controlled trials at 1–2 years
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were research waste. In research on non-skeletal end-
points, the marked imbalances between observational
studies and RCTs, and between RCTs with surrogate
and clinical endpoints suggest that waste in researching
calcium and vitamin D is not restricted to bone health.
In estimating that 85% of research represents waste
[1], Chalmers and Glasziou focused on four aspects - the
choice of research questions, quality of research, unpub-
lished results, and the quality of research reports. Our
findings are relevant to the first and second aspects.
Chalmers and Glasziou estimated that 50% of studies are
wasteful because they are unnecessary, poorly designed
without reference to a systematic review, and/or have
major methodological weaknesses [1]. Our findings sug-
gest that this may be a considerable underestimate, at
least in some research areas. Studies with weaker designs
(observational studies or RCTs with surrogate endpoints)
were far more prevalent than RCTs with clinical end-
points, but we considered almost all (90–98%) such
studies published over a 15–20 year period to represent
research waste. If our findings apply to other fields, the
overwhelming majority of RCTs and observational stud-
ies published in mature research areas may be wasteful.
A strength of our study is the extensive systematic lit-
erature searches and categorisation of large, complete
sets of observational studies and RCTs of calcium intake
and skeletal health, and RCTs of vitamin D supplements
published over a long period of time. We are not aware
of previous attempts to categorise or quantify research
waste, but our methods are very labour and time inten-
sive, and require adequate resourcing if they were to be
more widely utilised. Limitations include that only two
research areas were studied and therefore the results
might not apply to other fields, and that we estimated
the scope but not cost of the waste. We also considered
both study design and study endpoints, which we think
makes any conclusions more compelling than if the re-
search areas or the study design and endpoints were
assessed separately. Assessing studies as novel, contrib-
uting to clinical knowledge, or representing research
waste requires subjective decisions. In general, however,
agreement between the independent assessments was
high. Agreement was lowest for novelty because many
studies were of highly selected cohorts not previously
studied. Deciding whether small differences from previ-
ous cohorts (such as ethnicity, gender or age) are suffi-
ciently unique to be considered novel is difficult.
Replication of previous studies is essential, and while
disagreements may occur as to whether a study repre-
sents replication or redundancy, the number of observa-
tional studies and RCTs with surrogate endpoints
extended well beyond the number needed for replica-
tion. Research can take a long time from inception to
completion, and it is possible that some studies were
initiated before the tipping point but not published until
more than 5y after the tipping point, and were then
assessed as not contributing to current knowledge. The
literature search includes papers published until Septem-
ber 2014. As a methodological study, it was an extremely
comprehensive, but very time-consuming attempt to
identify all relevant clinical studies (observational and
RCT) for a large number of outcomes. This search took
almost 12 months to complete, and so it was not prac-
tical to update it subsequently. We are not aware of an
RCT of calcium or vitamin D with fracture as the pri-
mary endpoint reported since 2014. Based on the data
from 2011 to 2014, we would expect more than 75 ob-
servational studies to have been published since 2014,
but < 10 RCTs of calcium and > 200 RCTs of vitamin D
supplements. These recent publications are therefore
unlikely to alter our conclusions related to research
waste in this field.
An important issue raised by this research is how to
assess research waste. Widely accepted definitions of
waste are not yet available, and an element of subjectiv-
ity will always be required. To minimise the impact of
subjectivity, we followed approaches used for high qual-
ity evidence-based systematic reviews: we explicitly
stated the criteria for studies to be categorised as re-
search waste, independently assessed studies, docu-
mented levels of agreement, resolved disagreements by
consensus discussion, and reported our judgements for
each study. However, other researchers might classify
studies differently, and differences of opinion are com-
mon in similar circumstances. For example, Cochrane
researchers recently reported that 45/156 risk of bias
judgements differed between two groups of authors [11].
Differences in definitions and study classification be-
tween researchers might provide insight into this issue
and lead to better definitions of research waste, and bet-
ter approaches to its assessment.
A related issue is when the tipping point can be con-
sidered to have occurred. In the design phase of any
RCT, a literature review should be standard practice.
Thus, trialists should be aware of the most recent evi-
dence before the study protocol is finalised, and there-
fore whether RCTs with meaningful clinical endpoints
should be undertaken, or whether more observational
studies or RCTs with surrogate endpoints are still re-
quired. Researchers may have different views on the
exact date the tipping point occurred, but the cumula-
tive meta-analyses and publication rates of observational
studies highlight that it was many years ago that the hy-
pothesis of fracture prevention for both calcium and
vitamin D supplementation was formulated. The exact
date of the tipping point, and whether 5 years is suffi-
cient to allow dissemination of that information may be
open to debate, but, in our example, would not change
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the conclusion that the majority of recent published re-
search has not addressed the issue of fundamental clin-
ical importance- whether calcium or vitamin D
supplementation prevents fractures.
Research waste and how it can be reduced is increas-
ingly being considered an important topic [9, 12–19].
The suggestions most relevant to our findings are the
improvement of research priorities [9] and study design
[15], in particular, performing systematic reviews to in-
form research proposals, and ensuring that study
methods are optimum. Our finding that research waste
continues unabated for long periods of time after a hy-
pothesis has been generated or a research question has
been answered suggests that most academics and fun-
ders have not so far corrected this problem. Publication
of all RCTs is recommended, so if research has pro-
gressed to the stage of publication, it is difficult to argue
that the primary RCT results should not be published.
Considerable onus therefore necessarily falls upon as-
sessments performed at the funding or ethical approval
stage. These should be informed by a systematic review
[9, 20], but that may not be straightforward. If systematic
reviews exist, they often have discordant findings [21],
and “living” systematic reviews updated with new evi-
dence in real-time are not yet available [22]. Conducting
a systematic review is time-consuming but necessary if
one is not available or out-of-date. Finding relevant re-
search is difficult because bibliographic database
searches are non-specific, require screening of very
many titles and abstracts, and frequently miss relevant
studies. Involvement of information scientists and meth-
odological expertise in the appraisal of funding applica-
tions might help to reduce research waste. This would
require investment in appropriate resources but might
improve the efficiency and accuracy of research funding.
We found that a very high proportion of observational
research on calcium intake was wasteful. Many observa-
tional analyses are conducted opportunistically [23], and
journal reviewers and editors could play important roles
in declining manuscripts that examine established hy-
potheses that need, or have already been tested in, ran-
domised studies, or where the findings are fragile and
unlikely to be correct [24]. However, the large number
of journals courting publications and academic incen-
tives for publication quantity suggest that this strategy
may be difficult to realise.
Conclusion
We identified a very high proportion of research waste
in the fields of calcium intake and vitamin D supplemen-
tation for bone health after the need for RCTs with
meaningful clinical endpoints had been established. This
waste was largely due to continued publication of obser-
vational studies and RCTs with surrogate endpoints
unable to address the relevant clinical questions. Nearly
all the observational studies and nearly half the RCTs
were not novel and another third of RCTs added no new
clinical knowledge. Thus, collectively, 95% of recent
RCT or observational studies of calcium intake and
BMD or fracture, and 69% of recent RCTs of vitamin D
supplements and BMD or fracture were research waste.
Strategies to reduce research waste should be devised
and studied to determine their effectiveness.
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